SK Biopharmaceuticals signed an exclusive worldwide license with the Wisconsin Alumni Research Foundation (WARF) for WT‑7695, a preclinical radiopharmaceutical developed with the University of Wisconsin–Madison. The deal grants SK global R&D, manufacturing and commercialization rights and signals increased industry investment in targeted radiotherapies as oncology partners seek precision payload delivery to tumors. SK said the acquisition expands its oncology pipeline into radiopharma, where regulatory, manufacturing and dosimetry expertise will determine clinical and commercial pace.